This invention provides an alternative PET radiotracer using human serum albumin radio labelled with the gallium radioisotope 68Ga (68Ga-HSA) via a chelator conjugate of HSA with the chelator NOTA. The agents are useful as markers of blood volume, haemodynamic and lymphatic function and tissue inflammation in vivo. The other aspects of the invention are an automated kit-type preparation Of 68Ga-HSA at room temperature, in the range of about 19-25 ˚C, providing 68Ga-HSA on demand and an automated kit-type preparation of 68Ga- labeled HSA macroaggregates using microwave heating.
The invention provides a preparation of a ventilation/perfusion imaging agent comprising positron emitting 68Ga, produced, from a 68Ge/68Ga generator. The agent provides high quality images and quantification that make PET examinations available to improve the management of patients under critical conditions such as pulmonary embolism. Assessment of the ventilation distribution is part of the evaluation of lung function prior to lung resection and is also part of the diagnosis of pulmonary emboli.
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
The present invention relates to a method of obtaining 68Ga from a 68Ge/68Ga radioisotope generator and a method of preparing 68Ga-radiolabelled complexes using the obtained 68Ga. The method comprises elution of the generator with an aqueous chloride ion solution. The invention further relates to an apparatus for carrying out the 68Ga metal complex formation.
A61K 51/12 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo caractérisées par un aspect physique particulier, p. ex. émulsion, microcapsules, liposomes
C01G 15/00 - Composés du gallium, de l'indium ou du thallium
The present invention provides radioactive gallium complexes which comprise DOTA- biotin conjugates, incorporating a linker group. Also described are radiopharmaceutical compositions, and methods and uses of the complexes for in vivo imaging involving pre-targeting with avidin.
The present invention relates to the field of [18F] radiofluorination chemistry for the preparation of Positron Emission Tomography (PET) radioligands and [18F] radiofluorinating reagents. The invention further provides kits for preparation of the same.
A method and apparatus are provided for reducing motion related imaging artifacts. The method includes determining an internal motion for of two regions of the object, each region having a different level of motion, scanning the first region using a first scan protocol based on the motion, scanning a second region using a second different scan protocol based on the motion, and generating an image of the object based on the first and second regions.
G06K 9/00 - Méthodes ou dispositions pour la lecture ou la reconnaissance de caractères imprimés ou écrits ou pour la reconnaissance de formes, p.ex. d'empreintes digitales
The present invention relates to 18F radiochemistry and in particular to a method for synthesising radiofluorinated amides and amines. The method of the invention has particular application in the radiosynthesis of a variety of 18F-labelled positron emission tomography (PET) tracers.
Naphthoxazine derivatives which are selective ligands for the dopamine D2 receptor and which carry an 18F radiolabel suitable for imaging with PET are described. The compounds of the present invention are thus useful for in vivo diagnostics and in vivo imaging of the dopamine D2 receptor.
The present invention provides isatin 5-sulfonamide derivatives, pharmaceutical compositions comprising said derivatives, their use as molecular imaging agents, their use for the diagnosis or treatment of diseases or disorders associated with dysregulation of apoptosis, methods for synthesizing said derivatives, methods for the molecular imaging of caspase activity and apoptosis, and methods of assessing the therapeutic effect of a test substance on caspase activity.
C07D 403/12 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
10.
SYSTEM FOR DISPENSING A FLUID IN NON-CONTROLLED ENVIRONMENTS
The present invention provides a dispenser cassette (110) which provides at least one product dispense vial (122) to be filled. The cassette provides a filtrate conduit (128) extending between the dispense vial and a filter unit (116) so that flowpath (120) of the filtrate conduit and the dispense vial is provided and maintained as an environmentally-controlled, or GMP-compliant, volume. The resulting product dispensed into the dispense vial is thus dispensed in a GMP-compliant environment.
B65B 3/00 - Emballage de matériaux plastiques, de semi-liquides, de liquides ou de liquides et solides mélangés, dans des réceptacles ou récipients individuels, p. ex. dans des sacs ou sachets, boîtes, cartons, bidons ou pots
B65B 3/12 - Procédés ou moyens pour charger le matériau dans les réceptacles ou récipients en exerçant une pression sur le matériau mécaniquement, p. ex. par pistons ou pompes
B65B 55/02 - Stérilisation, p. ex. de paquets finis
Provided herein are methods for introducing flυorine atom onto a biomolecule comprising: (i) providing a linker comprising a thiol-reactive teminus and an azido/alkyne-reactive terminus; (ii) reacting the thiol-reactive terminus of the linker with a biomolecule comprising at least one thiol group or a reactive derivative thereof; and (iii) subsequently reacting the azido/alkyne-reactive terminus of the linker with a fluorine-substituted azide or alkyne respectively. Also provided are compositions and method of synthesis of bifunctional linkers and bioconjugates as well as radio-diagnostic agents comprising fluorine-labeled biomolecules.
The present invention provides a method for determination of neural activity in a sample. The method of the invention is useful for the determination of neural activity in both in vivo and in vitro samples and is particularly useful in providing diagnostic information in subjects suspected to have a neurological condition that leads to disturbed neurological signalling. Also provided by the invention are compounds suitable for use in the method of the invention, and a pharmaceutical composition useful for carrying out the method of the invention.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
13.
NUCLEOPHILIC RADIOFLUORINATION USING MICROFABRICATED DEVICES
A microscale solution for conducting [18F] fluoride phase transfer and subsequent radiosysnthesis of 2- [18F] FDG that eliminates the azeotropic drying process. [18F] fluoride phase transfer is performed using an inexpensive disposable microchip (310). Additionally, each subsequent each step may be performed on the same single microchip (310). The integrated microchip (310) provides a microchannel (312) having a first resin chamber, or reservoir, (314) for 18F transfer, a labelling reactor (316), a deprotection reactor (318), and a second resin chamber, or reservoir, (320) for purification.
The method calculates a scatter estimate for scatter correction of detection data from a subject in a positron emission tomographic scanner. The detection data represent the scattered events and unscattered events of annihilation photons emitted in the subject. The method uses the following steps: - determine an estimate of the unscattered events; - determine a simulation of the scattered events; - determine a value of a scaling factor by fitting the sum of the estimate of the unscat-tered events and a product of the scaling factor and the simulation of the scattered events to the detection data; and - determine the scatter estimate as the product of the scaling factor having said value and the simulation of the scattered events.
The present invention relates to the field of medical imaging, and in particular to imaging of disease states associated with the upregulation of the chemokine receptor 5 (CCR5). Imaging agents, precursors and methods are provided which are useful in imaging such disease states.
C07C 235/56 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné avec des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons simples, liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un cycle aromatique à six chaînons
C07D 211/62 - Atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile liés en position 4
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
The present invention relates to methods of synthesising radiolabelled compounds, to the precursors useful in such methods and to the radiolabelled compounds obtainable by such methods. More particularly, the present invention relate to methods, precursors and radiolabelled compounds useful in Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) especially for imaging neuroreceptors with radiolabelled agonists.
The present invention provides a method and an apparatus for extracting an isotope from a gas. More specifically, the present invention depicts a system that has been devised which provides [18F] fluoride from a cyclotron target in non-aqueous media.
G21G 1/10 - Dispositions pour la conversion des éléments chimiques par rayonnement électromagnétique, radiations corpusculaires ou bombardement par des particules, p. ex. production d'isotopes radioactifs à l'extérieur des réacteurs nucléaires ou des accélérateurs de particules par bombardement avec des particules électriquement chargées
G21G 4/08 - Sources radioactives autres que les sources de neutrons caractérisées par des aspects de leur structure spécialement adaptées aux applications médicales
The invention relates to methods and apparatus for drying [18F]fluoride which comprises (i) passing a [18F]fluoride solution comprising water, a solvent, [18F]fluoride, and a cationic counterion through a narrow bore vessel at elevated temperature such that the water and solvent are vaporised forming a vaporised component, and (ii) collecting the resulting vaporised component by condensing into a collection vessel.
The invention relates to methods and apparatus for purifying a radiolabelled compound. The method comprises (i) passing a crude reaction mixture comprising the desired radiolabelled compound and one or more contaminants in a solvent through a narrow bore vessel at elevated temperature such that the organic solvent and either the radiolabelled compound or one or more contaminants is vaporised forming a vaporised component, and (ii) collecting the resulting vaporised component by condensing into a collection vessel.
The invention relates to methods and apparatus for labelling a biologically active vector such as a peptide with reporter moiety such as a radionuclide. The methods comprise reaction of a compound of formula (I) with a compound of formula (II): R*-L2 -N3 (II) or, a compound of formula (III) with a compound of formula (IV) wherein: L1, L2, L3, and L4 are each Linker groups; R* is a reporter moiety; in a narrow bore copper vessel. Microfluidic devices for performing the methods of the invention are also claimed.
The invention relates to radiodiagnostic and radiotherapeutic agents, including biologically active vectors labelled with radionuclides. It further relates to methods and reagents labelling a vector such as a peptide comprising reaction of a compound of formula (I): with a compound of formula (II) or, a compound of formula (III): with a compound of formula (IV): in the presence of a Cu (I) catalyst. The resultant labelled conjugates are useful as diagnostic agents, for example, as radiopharmaceuticals more specifically for use in Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) or for radiotherapy.
brevets
